{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:40:32Z","timestamp":1791168032473,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.antiviral.2009.07.022","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T08:52:06Z","timestamp":1251363126000},"page":"91-100","source":"Crossref","is-referenced-by-count":182,"title":["Entry inhibitors in the treatment of HIV-1 infection"],"prefix":"10.1016","volume":"85","author":[{"given":"John C.","family":"Tilton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Doms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2009.07.022_bib1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.272.5270.1955","article-title":"CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1","volume":"272","author":"Alkhatib","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1006\/viro.1997.8673","article-title":"HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation","volume":"234","author":"Alkhatib","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2009.07.022_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/aid.1995.11.533","article-title":"Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates","volume":"11","author":"Allaway","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2009.07.022_bib4","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1073\/pnas.0811713106","article-title":"Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41","volume":"106","author":"Anastassopoulou","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib5","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/JVI.73.2.1719-1723.1999","article-title":"T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure","volume":"73","author":"Arakaki","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib6","doi-asserted-by":"crossref","first-page":"11456","DOI":"10.1074\/jbc.M111191200","article-title":"Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies","volume":"277","author":"Arthos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.07.022_bib7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.274.5294.1924","article-title":"Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines","volume":"274","author":"Atchison","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.01079-06","article-title":"Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652","volume":"51","author":"Baba","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib9","doi-asserted-by":"crossref","first-page":"10791","DOI":"10.1128\/JVI.76.21.10791-10800.2002","article-title":"Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding","volume":"76","author":"Basmaciogullari","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.282.12.1135","article-title":"HIV-1 drug resistance in newly infected individuals","volume":"282","author":"Boden","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.07.022_bib11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/QAI.0b013e31818c953f","article-title":"Chemokine analogues show suitable stability for development as microbicides","volume":"49","author":"Cerini","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.07.022_bib12","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.1128\/JVI.73.8.6598-6609.1999","article-title":"Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates","volume":"73","author":"Chabot","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core structure of gp41 from the HIV envelope glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03327","article-title":"Structure of an unliganded simian immunodeficiency virus gp120 core","volume":"433","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0092-8674(00)81313-6","article-title":"The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates","volume":"85","author":"Choe","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","article-title":"Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection","volume":"387","author":"Chun","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/44755","article-title":"Re-emergence of HIV after stopping therapy","volume":"401","author":"Chun","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","article-title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells","volume":"270","author":"Cocchi","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1084\/jem.185.4.621","article-title":"Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 infected individuals","volume":"185","author":"Connor","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib20","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1128\/JVI.76.17.8953-8957.2002","article-title":"The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor","volume":"76","author":"Cormier","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib21","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1128\/JVI.75.12.5541-5549.2001","article-title":"Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120\u2013CD4 complexes","volume":"75","author":"Cormier","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib22","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1073\/pnas.87.17.6574","article-title":"High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates","volume":"87","author":"Daar","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib23","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.66.11.6777-6780.1992","article-title":"Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution","volume":"66","author":"De Jong","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib24","doi-asserted-by":"crossref","first-page":"882","DOI":"10.7326\/0003-4819-127-10-199711150-00004","article-title":"Association between CCR5 genotype and the clinical course of HIV-1 infection","volume":"127","author":"de Roda Husman","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib25","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","article-title":"Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study","volume":"273","author":"Dean","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1086\/510531","article-title":"Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen","volume":"195","author":"Deeks","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/381661a0","article-title":"Identification of a major co-receptor for primary isolates of HIV-1","volume":"381","author":"Deng","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib28","doi-asserted-by":"crossref","first-page":"8358","DOI":"10.1128\/JVI.74.18.8358-8367.2000","article-title":"Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120","volume":"74","author":"Derdeyn","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jama.280.17.1497","article-title":"Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators","volume":"280","author":"Detels","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2009.07.022_bib30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/08892220151126508","article-title":"Safe use of the CXCR4 inhibitor ALX40-4C in humans","volume":"17","author":"Doranz","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2009.07.022_bib31","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1128\/JVI.73.4.2752-2761.1999","article-title":"Identification of CXCR4 domains that support coreceptor and chemokine receptor functions","volume":"73","author":"Doranz","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0092-8674(00)81314-8","article-title":"A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors","volume":"85","author":"Doranz","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib33","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1128\/AAC.49.11.4721-4732.2005","article-title":"Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity","volume":"49","author":"Dorr","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/381667a0","article-title":"HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5","volume":"381","author":"Dragic","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib35","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1128\/JVI.66.8.4748-4756.1992","article-title":"Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity","volume":"66","author":"Dubay","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib36","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1073\/pnas.0701478104","article-title":"Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus","volume":"104","author":"Dwyer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib37","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.94.8.4005","article-title":"Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains","volume":"94","author":"Edinger","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib39","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib40","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1128\/JVI.66.5.3183-3187.1992","article-title":"Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule","volume":"66","author":"Fouchier","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0092-8674(00)80694-7","article-title":"DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells","volume":"100","author":"Geijtenbeek","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib42","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/00002030-200311070-00009","article-title":"Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine","volume":"17","author":"Gulick","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib44","doi-asserted-by":"crossref","first-page":"e1000360","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2009.07.022_bib45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJM199610103351501","article-title":"A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team","volume":"335","author":"Hammer","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib46","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1073\/pnas.0807335105","article-title":"Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains","volume":"105","author":"He","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.07.022_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1149","article-title":"Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease","volume":"34","author":"Hernandez","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.antiviral.2009.07.022_bib49","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1128\/JVI.80.8.4017-4025.2006","article-title":"Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events","volume":"80","author":"Ho","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib50","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1073\/pnas.96.11.6359","article-title":"Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein","volume":"96","author":"Hoffman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib51","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1126\/science.1145373","article-title":"Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4","volume":"317","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib52","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1126\/science.1118398","article-title":"Structure of a V3-containing HIV-1 gp120 core","volume":"310","author":"Huang","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib53","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib54","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1349-7006.2009.01104.x","article-title":"Efficient inhibition of SDF-1alpha-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists","volume":"100","author":"Iwasaki","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.antiviral.2009.07.022_bib55","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/592169","article-title":"Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults","volume":"198","author":"Jacobson","year":"2008","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/mol.107.035055","article-title":"CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor","volume":"72","author":"Ji","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/365113a0","article-title":"HIV-1 inhibition by a peptide","volume":"365","author":"Jiang","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1128\/JCM.32.2.364-370.1994","article-title":"MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection","volume":"32","author":"Karlsson","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib59","doi-asserted-by":"crossref","first-page":"11807","DOI":"10.1128\/JVI.78.21.11807-11815.2004","article-title":"Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype","volume":"78","author":"Karlsson","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib60","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0802203105","article-title":"Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection","volume":"105","author":"Keele","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2009.07.022_bib62","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","author":"Kitahata","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib63","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1128\/AAC.01057-08","article-title":"Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir\u2013ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope","volume":"53","author":"Kitrinos","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/135965350501000205","article-title":"Sensitivity of primary R5 HTV-1 to inhibition by RANTES correlates with sensitivity to small-molecule R5 inhibitors","volume":"10","author":"Koning","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2009.07.022_bib65","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1086\/377105","article-title":"Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection","volume":"188","author":"Koning","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib66","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/380802","article-title":"Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1","volume":"189","author":"Kuritzkes","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib67","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib68","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000183633.06580.8a","article-title":"Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults","volume":"19","author":"Lalezari","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib69","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/427993","article-title":"T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen","volume":"191","author":"Lalezari","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/00002030-200303280-00007","article-title":"A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy","volume":"17","author":"Lalezari","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib71","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.1099288","article-title":"Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5","volume":"306","author":"Lederman","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib72","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1074\/jbc.274.14.9617","article-title":"Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function","volume":"274","author":"Lee","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.07.022_bib73","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/S0021-9258(18)86956-3","article-title":"Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells","volume":"265","author":"Leonard","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.07.022_bib74","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.antiviral.2009.07.022_bib75","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1128\/JVI.77.2.931-942.2003","article-title":"Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins","volume":"77","author":"Lin","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib76","doi-asserted-by":"crossref","first-page":"11013","DOI":"10.1073\/pnas.1832214100","article-title":"A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding","volume":"100","author":"Lin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib77","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib78","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","article-title":"Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions","volume":"131","author":"Lucas","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib79","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/00002030-200006160-00012","article-title":"Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study","volume":"14","author":"Maas","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib80","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/JVI.78.7.3742-3752.2004","article-title":"Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155","volume":"78","author":"Madani","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib81","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/JVI.01764-08","article-title":"Estimating the stoichiometry of human immunodeficiency virus entry","volume":"83","author":"Magnus","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib82","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt768","article-title":"Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes","volume":"21","author":"Martin","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd1331","article-title":"Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes","volume":"3","author":"Matthews","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2009.07.022_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/504693","article-title":"HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response","volume":"194","author":"Melby","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib85","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1097\/QAD.0b013e3282f12362","article-title":"Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy","volume":"21","author":"Melby","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib86","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1097-1160","article-title":"The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression","volume":"3","author":"Michael","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib87","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1128\/JVI.67.9.5623-5634.1993","article-title":"V3 loop of the human immunodeficiency virus type 1 Env protein: interpreting sequence variability","volume":"67","author":"Milich","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2009.02.046","article-title":"HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes","volume":"137","author":"Miyauchi","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib89","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JVI.72.5.3623-3634.1998","article-title":"Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans","volume":"72","author":"Mondor","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib90","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/JVI.66.8.4784-4793.1992","article-title":"A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells","volume":"66","author":"Moore","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib91","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1128\/JVI.73.5.3544-3550.1999","article-title":"Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants","volume":"73","author":"Mosier","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib92","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/JVI.74.4.1948-1960.2000","article-title":"Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120","volume":"74","author":"Moulard","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib93","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/AAC.01727-08","article-title":"The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib94","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib95","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/382833a0","article-title":"The CXC chemokine SDF-1 is the ligand for LESTR\/fusin and prevents infection by T-cell-line-adapted HIV-1","volume":"382","author":"Oberlin","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib96","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.virol.2007.12.009","article-title":"Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120","volume":"373","author":"Ogert","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2009.07.022_bib97","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib98","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0b013e328325a4cd","article-title":"Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors","author":"Pan","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib99","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/clinids\/23.4.685","article-title":"Drug interactions in patients infected with human immunodeficiency virus","volume":"23","author":"Piscitelli","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib100","doi-asserted-by":"crossref","first-page":"12266","DOI":"10.1128\/JVI.75.24.12266-12278.2001","article-title":"Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region","volume":"75","author":"Platt","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib101","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jmv.20141","article-title":"Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure","volume":"74","author":"Poveda","year":"2004","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib102","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2006.11.004","article-title":"HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry","volume":"361","author":"Pugach","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2009.07.022_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2009.02.044","article-title":"Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities","author":"Pugach","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2009.07.022_bib104","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0140-6736(05)62697-9","article-title":"32bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes","volume":"349","author":"Rappaport","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.07.022_bib105","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/JVI.02496-08","article-title":"HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide","volume":"83","author":"Ray","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib106","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/JVI.02413-06","article-title":"Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors","volume":"81","author":"Ray","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib107","doi-asserted-by":"crossref","first-page":"16249","DOI":"10.1073\/pnas.252469399","article-title":"Sensitivity of HIV-1 to entry inhibitors correlates with envelope\/coreceptor affinity, receptor density, and fusion kinetics","volume":"99","author":"Reeves","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib108","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1128\/JVI.79.8.4991-4999.2005","article-title":"Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization","volume":"79","author":"Reeves","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib109","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1099\/vir.0.81111-0","article-title":"Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency","volume":"86","author":"Repits","year":"2005","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib110","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/infdis\/169.5.968","article-title":"The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression","volume":"169","author":"Richman","year":"1994","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.07.022_bib111","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81364-1","article-title":"Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity","volume":"87","author":"Rucker","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib112","doi-asserted-by":"crossref","first-page":"24934","DOI":"10.1074\/jbc.272.40.24934","article-title":"The second extracellular loop of CCR5 is the major determinant of ligand specificity","volume":"272","author":"Samson","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2009.07.022_bib113","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib114","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/nm1197-1259","article-title":"In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression","volume":"3","author":"Scarlatti","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib115","doi-asserted-by":"crossref","first-page":"10973","DOI":"10.1021\/bi061193r","article-title":"Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120","volume":"45","author":"Schon","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.antiviral.2009.07.022_bib116","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1128\/JVI.66.3.1354-1360.1992","article-title":"Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population","volume":"66","author":"Schuitemaker","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib117","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1073\/pnas.0307953101","article-title":"Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins","volume":"101","author":"Si","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib118","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.276.5310.276","article-title":"Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist","volume":"276","author":"Simmons","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib119","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jmv.21138","article-title":"Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations","volume":"80","author":"Soria","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0092-8674(86)90778-6","article-title":"Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III\/LAV, the retrovirus of AIDS","volume":"45","author":"Starcich","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2009.07.022_bib121","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/AAC.00013-07","article-title":"Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects","volume":"51","author":"Stone","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib122","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1128\/AAC.49.12.4911-4919.2005","article-title":"Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1","volume":"49","author":"Strizki","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib123","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/31261","article-title":"The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract","volume":"393","author":"Tachibana","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib124","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1021\/jm0304515","article-title":"Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperaz inyl]-4-methylpiperidine (Sch-417690\/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist","volume":"47","author":"Tagat","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2009.07.022_bib125","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1006\/bbrc.1994.2868","article-title":"Structure-activity relationships of an anti-HIV peptide, T22","volume":"205","author":"Tamamura","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2009.07.022_bib126","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1006\/bbrc.1998.9871","article-title":"A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140","volume":"253","author":"Tamamura","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2009.07.022_bib127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00042560-200010010-00001","article-title":"Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100","volume":"25","author":"Tremblay","year":"2000","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2009.07.022_bib128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/384184a0","article-title":"CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5","volume":"384","author":"Trkola","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1128\/JVI.75.2.579-588.2001","article-title":"Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140","volume":"75","author":"Trkola","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1073\/pnas.012519099","article-title":"HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use","volume":"99","author":"Trkola","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib131","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1128\/JVI.69.11.6609-6617.1995","article-title":"Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG","volume":"69","author":"Trkola","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib132","doi-asserted-by":"crossref","first-page":"10531","DOI":"10.1073\/pnas.0802666105","article-title":"Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249","volume":"105","author":"Veazey","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib133","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature04055","article-title":"Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion","volume":"438","author":"Veazey","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib134","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/00002030-200005260-00013","article-title":"Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel","volume":"14","author":"Wegner","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2009.07.022_bib135","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib136","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/387426a0","article-title":"Atomic structure of the ectodomain from HIV-1 gp41","volume":"387","author":"Weissenhorn","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib137","doi-asserted-by":"crossref","first-page":"16828","DOI":"10.1073\/pnas.0708109104","article-title":"Potent D-peptide inhibitors of HIV-1 entry","volume":"104","author":"Welch","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib138","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1128\/JVI.80.10.4909-4920.2006","article-title":"Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir","volume":"80","author":"Westby","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib139","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/JVI.02006-06","article-title":"Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry","volume":"81","author":"Westby","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib140","doi-asserted-by":"crossref","first-page":"12676","DOI":"10.1073\/pnas.91.26.12676","article-title":"Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex","volume":"91","author":"Wild","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib141","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/aid.1993.9.1051","article-title":"A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell\u2013cell fusion","volume":"9","author":"Wild","year":"1993","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.antiviral.2009.07.022_bib142","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1073\/pnas.89.21.10537","article-title":"A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition","volume":"89","author":"Wild","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib143","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","article-title":"Recovery of replication-competent HIV despite prolonged suppression of plasma viremia","volume":"278","author":"Wong","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2009.07.022_bib144","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/384179a0","article-title":"CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5","volume":"384","author":"Wu","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib145","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1084\/jem.186.8.1373","article-title":"Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding","volume":"186","author":"Wu","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2009.07.022_bib146","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1006\/viro.1997.8924","article-title":"CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage","volume":"240","author":"Xiao","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2009.07.022_bib147","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/AAC.49.3.1113-1119.2005","article-title":"Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41","volume":"49","author":"Xu","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2009.07.022_bib148","doi-asserted-by":"crossref","first-page":"12132","DOI":"10.1128\/JVI.79.19.12132-12147.2005","article-title":"Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1","volume":"79","author":"Yang","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib149","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(98)12262-6","article-title":"Transmission of antiretroviral-drug-resistant HIV-1 variants","volume":"354","author":"Yerly","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.07.022_bib150","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1128\/JVI.72.6.5035-5045.1998","article-title":"In vivo distribution of the human immunodeficiency virus\/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5","volume":"72","author":"Zhang","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2009.07.022_bib151","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2009.07.022_bib152","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","article-title":"Distribution and three-dimensional structure of AIDS virus envelope spikes","volume":"441","author":"Zhu","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.07.022_bib153","doi-asserted-by":"crossref","first-page":"e1000203","DOI":"10.1371\/journal.ppat.1000203","article-title":"Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs","volume":"4","author":"Zhu","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2009.07.022_bib154","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"Zou","year":"1998","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209003945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354209003945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T13:53:26Z","timestamp":1685109206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354209003945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0166354209003945"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.07.022","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}